Table 2.

Responder rates (with 95 % CI) after 12 months of treatment

Responder ratea (%)	Ibandronate
	Oral 100 mg/month	IV 1 mg/month
Patients with >0 % increase in BMD
L2–L4	91.8 (86.8, 95.3)	92.1 (87.2, 95.5)
Total hip	86.2 (80.3, 90.9)	91.5 (86.6, 95.1)
Femoral neck	71.3 (64.1, 77.7)	74.1 (67.2, 80.2)
Patients with ≥3 % increase in BMD
L2–L4	71.6 (64.5, 78.0)	75.7 (68.9, 81.6)
Total hip	39.2 (32.1, 46.7)	43.4 (36.2, 50.8)
Femoral neck	43.1 (35.8, 50.6)	41.8 (34.7, 49.2)

BMD bone mineral density, CI confidence interval, IV intravenous

^aDefined as the proportion of patients with mean lumbar spine (L2–L4), total hip, or femoral neck BMD above baseline